Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v7-FR
Language English French
Date Updated 2021-10-27 2021-10-27
Drug Identification Number 02409968 02409968
Brand name CEFTRIAXONE FOR INJECTION CEFTRIAXONE FOR INJECTION
Common or Proper name CefTRIAXone for Injection 100 g SmartPak® CefTRIAXone for Injection 100 g SmartPak®
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients CEFTRIAXONE CEFTRIAXONE
Strength(s) 100G 100G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size SmartPak SmartPak
ATC code J01DD J01DD
ATC description OTHER BETA-LACTAM ANTIBACTERIALS OTHER BETA-LACTAM ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-11-01 2021-11-01
Actual start date 2021-11-01 2021-11-01
Estimated end date 2021-12-01 2021-12-01
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to production delays, we will be encountering supply interruptions on our Ceftriaxone for Injection SmartPak. Fresenius Kabi Canada Ltd. regrets to advise that due to production delays, we will be encountering supply interruptions on our Ceftriaxone for Injection SmartPak.
Health Canada comments